Oncotelic's Injectable Everolimus Shows Promise in Boosting Drug Bioavailability for Breast Cancer Treatment
TL;DR
Oncotelic Therapeutics' Sapu003 technology could provide a competitive advantage by dramatically increasing drug bioavailability from 10% to near 100% for breast cancer treatment.
Oncotelic's Deciparticles technology creates sub-20nm nanoparticles that enable injectable Everolimus to achieve 80-100% bioavailability compared to 10% with oral administration.
This advancement could significantly improve breast cancer treatment outcomes by delivering more consistent and effective medication to patients in need.
Oncotelic's nanoparticle technology transforms a common cancer drug into an injectable form that could work up to ten times more effectively than current oral versions.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics Inc. has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable formulation of Everolimus (marketed as Afinitor) that could revolutionize breast cancer treatment by significantly improving drug bioavailability. The development represents a potential breakthrough in oncology therapeutics, addressing one of the fundamental challenges in cancer drug delivery.
The Sapu003 formulation utilizes Oncotelic's proprietary Deciparticles technology, which creates sub-20nm nanoparticles designed to enhance drug absorption and distribution throughout the body. This technological advancement could transform the effectiveness of Everolimus, a drug currently administered as an oral pill with approximately 10% bioavailability. Preclinical studies indicate the injectable Sapu003 formulation could boost bioavailability to between 80% and 100%, representing a potential eight to tenfold improvement in drug delivery efficiency.
Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, emphasized the company's strategic focus on de-risked, late-stage assets during a recent interview on the BioMedWire podcast. The company's approach centers on accelerating development through regulatory pathways designed for speed and efficiency, potentially bringing improved treatments to patients more rapidly.
The implications of this development extend beyond breast cancer treatment. Higher bioavailability could lead to dramatically improved, faster, and more consistent efficacy for patients, potentially reducing required dosages while maintaining therapeutic effects. This advancement addresses a critical limitation in current cancer therapeutics where poor bioavailability often compromises treatment outcomes and requires higher drug concentrations that can increase side effects.
Sapu Nano, the developer of the Deciparticles technology, operates as part of Oncotelic's GMP Bio joint venture established with Dragon Overseas Capital Limited. The technology platform represents a significant innovation in nanomedicine, with potential applications across multiple therapeutic areas beyond oncology. The successful development of Sapu003 could establish a new paradigm for drug formulation, particularly for medications that currently suffer from poor oral bioavailability.
The progression to Phase 1 trials marks a critical milestone for Oncotelic Therapeutics, a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. The company's latest developments and updates are available through their newsroom at ibn.fm/OTLC. The successful implementation of this technology could have far-reaching implications for drug development across multiple therapeutic categories, potentially improving treatment outcomes while reducing side effects and treatment costs.
Curated from InvestorBrandNetwork (IBN)
